| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.3 | 0.07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.092 | 0.07 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.3 | 0.07 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.07 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.07 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.064 | 0.08 |